Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Antengene Announces Clearance of U.S. IND for the Phase I Trial

Thursday, May 18, 2023

Antengene Corporation announced that the Investigational New Drug (IND) for a Phase I study of the first-in-class anti-CD24 monoclonal antibody ATG-031 has received clearance from the U.S. Food and Drug Administration (FDA).

ATG-031 is a first-in-class humanised anti-CD24 monoclonal antibody which inhibits the “don’t eat me” signal in the tumour microenvironment (TME). ATG-031 was designed to specifically bind with the CD24 expressed on cancer cells with high affinity and block the interaction between CD24 and the Siglec-10 receptor expressed on the surface of tumour associated macrophages (TAMs), to enhance the macrophage-mediated phagocytosis of cancer cells and promote cytotoxic T-cell function in the tumour microenvironment.

The PERFORM trial is a first-in-human, multi-centre, open-label, Phase I dose-finding study of ATG-031 in patients with advanced solid tumours or B-NHL. The primary objective of the study is to evaluate the safety and tolerability of ATG-031 as a monotherapy, and to determine the appropriate dose for Phase II studies.

ATG-031 is the world’s first anti-CD24 antibody to be advanced to the clinic in oncology and Antengene’s third drug candidate cleared to enter clinical studies in the U.S. The potential role of ATG-031 is supported by robust preclinical data that showed potent single agent in vivo efficacy and synergistic effects with chemotherapy or checkpoint inhibitors (CPIs).

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024